1994
DOI: 10.1007/bf03258493
|View full text |Cite
|
Sign up to set email alerts
|

Interferon beta-1b in Multiple Sclerosis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

1994
1994
2020
2020

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(1 citation statement)
references
References 25 publications
0
1
0
Order By: Relevance
“…2,3 This medication is administered either as INFβ-1a; a natural form 1 or INFβ-1b; a non-glycosylated form. [4][5][6] The amount which the human body produces is not sufficient to fully cure the disease, therefore finding another source is necessary. In this regard, the development of biotechnological procedures has paved the way to massive production using bacterial variants.…”
Section: Introductionmentioning
confidence: 99%
“…2,3 This medication is administered either as INFβ-1a; a natural form 1 or INFβ-1b; a non-glycosylated form. [4][5][6] The amount which the human body produces is not sufficient to fully cure the disease, therefore finding another source is necessary. In this regard, the development of biotechnological procedures has paved the way to massive production using bacterial variants.…”
Section: Introductionmentioning
confidence: 99%